Of mice and men: Bridging the translational disconnect in cns drug discovery

CNS Drugs

Volumn 23, Issue 11, 2009, Pages 915-926

  Geerts, Hugo ^a  

^a In Silico Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BL 1020; CATECHOL METHYLTRANSFERASE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; HOMOTAURINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; PLACEBO; RHODOPSIN; RISPERIDONE; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN METABOLISM; CLINICAL TRIAL; COGNITIVE DEFECT; DNA POLYMORPHISM; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG SCREENING; DRUG TARGETING; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NOTE; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SOCIAL INTERACTION; SPECIES COMPARISON; TRANSGENIC ANIMAL; TREATMENT FAILURE; TREATMENT RESPONSE;

ALZHEIMER DISEASE; ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; SCHIZOPHRENIA; SPECIES SPECIFICITY;

EID: 70350338847     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11310890-000000000-00000     Document Type: Note

References (68)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004 Aug; 3 (8): 711-715
2. Alzheimer Research Forum. Live discussion: mice on trial? Issues in the design of drug studies [online]. Available from URL: http://www.alzforum.org/ res/for/journal/detail.asp? liveID=168 [Accessed 2009 Jul 23]
3. Akhtar AZ, Pippin JJ, Sandusky CB. Animal models in spinal cord injury: a review. Rev Neurosci 2008; 19 (1): 47-60
4. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998 Aug 28; 281 (5381): 1349-1352
5. Ryman D, Lamb BT. Genetic and environmental modifiers of Alzheimer's disease phenotypes in the mouse. Curr Alzheimer Res 2006 Dec; 3 (5): 465-473
6. Lassalle JM, Halley H, Daumas S, et al. Effects of the genetic background on cognitive performances of TG2576 mice. Behav Brain Res 2008 Aug 5; 191 (1): 104-110
7. Gloriam DE, Fredriksson R, Schioth HB. The G protein-coupled receptor subset of the rat genome. BMC Genomics 2007 Sep 25; 8: 338-345
8. Sullivan RM. Hemispheric asymmetry in stress processing in rat prefrontal cortex and the role of mesocortical dopa-mine. Stress 2004 Jun; 7 (2): 131-143
9. Muly EC, Maddox M, Smith Y. Distribution of mGluR1 alpha and mGluR5 immunolabeling in primate prefrontal cortex. J Comp Neurol 2003; 467 (4): 521-535
10. Tooney PA, Au GG, Chahl LA. Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex. Neurosci Lett 2000; 283 (3): 185-188
11. Whitty CJ, Paul MA, Bannon MJ. Neurokinin receptor mRNA localization in human midbrain dopamine neurons. J Comp Neurol 1997; 382 (3): 394-400
12. Marazziti D, Betti L, Giannaccini G, et al. Distribution of [3H]GR65630 binding in human brain postmortem. Neurochem Res 2001 Mar; 26 (3): 187-190
13. Hewlett WA, Fridman S, Trivedi BL, et al. Characterization of desamino-5-[125I]iodo-3-methoxy-zacopride ([125I]MI-ZAC) binding to 5-HT3 receptors in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 1998 Feb; 22 (2): 397-410
14. Hirst WD, Abrahamsen B, Blaney FE, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003 Dec; 64 (6): 1295-1308
15. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993 Aug; 43 (8): 1467-1472 (Pubitemid 23230526)
16. Raffai RL, Dong LM, Farese Jr RV, et al. Introduction of human apolipoprotein E4 ''domain interaction'' into mouse apolipoprotein E. Proc Natl Acad Sci U S A 2001 Sep 25; 98 (20): 11587-11591
17. Loring JF, Paszty C, Rose A, et al. Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. Neurobiol Aging 1996 Mar-Apr; 17 (2): 173-182
18. Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 2007 Sep; 17 Suppl. 1: i171-81
19. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004 Oct; 161 (10): 1798-1805
20. Salminen M, Lundstrom K, Tilgmann C, et al. Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 1990 Sep 14; 93 (2): 241-247 (Pubitemid 20350764)
21. Babovic D, O'Tuathaigh CM, O'Sullivan GJ, et al. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav Brain Res 2007 Nov 2; 183 (2): 236-239
22. Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/ pharmacodynamic approach. Basic Clin Pharmacol Toxicol 2005 Mar; 96 (3): 182-192
23. Katoh M, Tateno C, Yoshizato K, et al. Chimeric mice with humanized liver. Toxicology 2008 Apr 3; 246 (1): 9-17
24. Kapur S, VanderSpek SC, Brownlee BA, et al. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003 May; 305 (2): 625-631
25. Ikonomovic MD, Abrahamson EE, Isanski BA, et al. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 2007 Sep; 64 (9): 1312-1317
26. Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007 Nov 27; 4 (11): e338
27. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007 Nov; 130 Pt 11: 2837-2844
28. Korczyn A. The amyloid cascade hypothesis. Alzheimers Dement 2008; 4: 176-178
29. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29 (10): 1456-1465
30. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008 Aug; 33 (9): 2061-2079
31. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000 Jul 5; 97 (14): 8104-8109
32. Bredeloux P, Dubuc I, Costentin J. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol 2007 Mar; 150 (6): 711-719
33. Boileau I, Dagher A, Leyton M, et al. Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine. J Neurosci 2007 Apr 11; 27 (15): 3998-4003
34. Suri RE. TD models of reward predictive responses in dopamine neurons. Neural Netw 2002 Jun-Jul; 15 (4-6): 523-533
35. Wanjerkhede SM, Bapi RS. Modeling the sub-cellular signaling pathways involved in reinforcement learning at the striatum. Prog Brain Res 2008; 168: 193-206
36. Roberts WA, Feeney MC, Macpherson K, et al. Episodic-like memory in rats: is it based on when or how long ago? Science 2008 Apr 4; 320 (5872): 113-115
37. Skelley SL, Goldberg TE, Egan MF, et al. Verbal and visual memory: characterizing the clinical and intermediate phe-notype in schizophrenia. Schizophr Res 2008 Oct; 105 (1-3): 78-85
38. Howard AR. Further validation studies of the Wechsler Memory Scale. Clin Psychol 1954 Apr; 10 (2): 164-167
39. Traykov L, Raoux N, Latour F, et al. Executive functions deficit in mild cognitive impairment. Cogn Behav Neurol 2007 Dec; 20 (4): 219-224
40. Carlson JM, Doyle J. Highly optimized tolerance: robustness and design in complex systems. Phys Rev Lett 2000 Mar 13; 84 (11): 2529-2532
41. Nayak S, Salim S, Luan D, et al. A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials. PLoS One 2008 Apr 23; 3 (4): e2016
42. Hagmann P, Cammoun L, Gigandet X, et al. Mapping the structural core of human cerebral cortex. PLoS Biol 2008 Jul 1; 6 (7): e159
43. Sambataro F, Murty VP, Callicott JH, et al. Age-related alterations in default mode network: impact on working memory performance. Neurobiol Aging. Epub 2008 Jul 30
44. Winder R, Cortes CR, Reggia JA, et al. Functional connectivity in fMRI: modeling approach for estimation and for relating to local circuits. Neuroimage 2007 Feb 1; 34 (3): 1093-1107 (Pubitemid 46394476)
45. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000 Apr; 157 (4): 514-520
46. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 Jun; 60 (6): 553-564
47. Stroup T. Heterogeneity of treatment effects in schizophrenia. Am J Med 2007 Apr; 120 (4 Suppl. 1): S26-31
48. Wong EH, Nikam SS, Shahid M. Multi-and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 2008 Jan; 9 (1): 28-36
49. Nudelman A, Gil-Ad I, Shpaisman N, et al. A mutual prodrug ester of GABA and perphenazine exhibits anti-schizophrenic efficacy with diminished extrapyramidal effects. J Med Chem 2008 May 8; 51 (9): 2858-2862
50. ClinicalTrials.gov. Available from URL, http://www.clinicaltrials.gov/ ct2/results?term=Alzheimer [Accessed, 2009, Jul 23]
51. Cambridge Healthtech Associates. Our mission [online]. Available from URL: http://www.chacorporate.com/pages/55-our-mission.cfm [Accessed 2009 Jul 23]
52. Cambridge Healthtech Associates. Toxicokinetics (TK) optimization [online]. Available from URL: http://www.chacorporate.com/pages/91- toxicokinetics-tk-optimization.cfm [Accessed 2009 Jul 23]
53. Montague PR, King-Casas B, Cohen JD. Imaging valuation models in human choice. Annu Rev Neurosci 2006; 29: 417-448
54. Grill-Spector K, Sayres R, Ress D. High-resolution imaging reveals highly selective nonface clusters in the fusiform face area. Nat Neurosci 2006 Sep; 9 (9): 1177-1185
55. Mitchell TM, Shinkareva SV, Carlson A, et al. Predicting human brain activity associated with the meanings of nouns. Science 2008 May 30; 320 (5880): 1191-1195
56. Yoshimura M, Koenig T, Irisawa S, et al. A pharmaco-EEG study on antipsychotic drugs in healthy volunteers. Psychopharmacology (Berl) 2007 May; 191 (4): 995-1004
57. Ahnaou A, Nayak S, Heylen A, et al. Sleep and EEG profile in neonatal hippocampal lesion model of schizophrenia. Physiol Behav 2007 Oct 22; 92 (3): 461-467
58. Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009 Feb 15; 65 (4): 289-295
59. Holmes HM, Sachs GA, Shega JW, et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc 2008 Jul; 56 (7): 1306-1311
60. Geerts H. Drug evaluation: (R)-flurbiprofen an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs 2007 Feb; 10 (2): 121-133
61. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease: the pivotal role of brain M1 receptors. Neurodegener Dis 2008; 5 (3-4): 237-240
62. Menzies L, Ooi C, Kamath S, et al. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007 Feb; 64 (2): 156-167
63. Kirschner M. The meaning of systems ioilogy. Cell 2005; 121 (4): 503-504
64. Bangs A. Predictive biosimulation and virtual patients in pharmaceutical R and D. Stud Health Technol Inform 2005; 111: 37-42
65. Cappuccio A, Elishmereni M, Agur Z. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res 2006 Jul 15; 66 (14): 7293-7300
66. Hodgkin AL, Huxley AF. A quantitative description of membrane currents and its application to conduction and excitation in nerve. J Physiol 1952; 117 (4): 500-544
67. De Schutter E. Why are computational neuroscience and systems biology so separate? PLoS Comput Biol 2008 May 30; 4 (5): e1000078
68. Erdi P, Kiss T, Toth J, et al. From systems biology to dynamical neuropharmacology: proposal for a new methodology. Syst Biol (Stevenage) 2006 Jul; 153 (4): 299-308